Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling Through ROR1 in Metastatic Castration-Resistant Prostate Cancer

Overview

Journal Cancer Res

Specialty Oncology

Date 2022 Feb 8

PMID 35131873

Authors

Fen Ma

Seiji Arai

Keshan Wang

Carla Calagua

Amanda R Yuan

Larysa Poluben

Zhongkai Gu

Joshua W Russo

David J Einstein

Huihui Ye

Meng Xiao He

Yu Liu

Eliezer Van Allen

Adam G Sowalsky

Manoj K Bhasin

Xin Yuan

Steven P Balk

Affiliations

Soon will be listed here.

Abstract

Significance: This work provides fundamental insights into Wnt signaling and prostate cancer cell biology and indicates that a subset of prostate cancer driven by autocrine Wnt signaling is sensitive to Wnt synthesis inhibitors.

Citing Articles

Deciphering the Tumor Microenvironment in Prostate Cancer: A Focus on the Stromal Component.

Pakula H, Pederzoli F, Fanelli G, Nuzzo P, Rodrigues S, Loda M Cancers (Basel). 2024; 16(21).

PMID: 39518123 PMC: 11544791. DOI: 10.3390/cancers16213685.

Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota.

Chen L, Xu Y, Wang Y, Ren Y, Dong X, Wu P Mol Cancer. 2024; 23(1):229.

PMID: 39395984 PMC: 11470719. DOI: 10.1186/s12943-024-02137-1.

Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization.

Yu G, Corn P, Mak C, Liang X, Zhang M, Troncoso P Proc Natl Acad Sci U S A. 2024; 121(33):e2402903121.

PMID: 39102549 PMC: 11331113. DOI: 10.1073/pnas.2402903121.

Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer.

Choi S, Pan E, Elliott A, Beltran H, Panian J, Jamieson C Mol Cancer Res. 2024; 22(10):920-931.

PMID: 38912907 PMC: 11850019. DOI: 10.1158/1541-7786.MCR-24-0395.

Wnt5a/β-catenin-mediated epithelial-mesenchymal transition: a key driver of subretinal fibrosis in neovascular age-related macular degeneration.

Liu D, Du J, Xie H, Tian H, Lu L, Zhang C J Neuroinflammation. 2024; 21(1):75.

PMID: 38532410 PMC: 10967154. DOI: 10.1186/s12974-024-03068-w.

References

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

Sun Y, Campisi J, Higano C, Beer T, Porter P, Coleman I . Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012; 18(9):1359-68. PMC: 3677971. DOI: 10.1038/nm.2890. View

Zhang L, Shay J . Multiple Roles of APC and its Therapeutic Implications in Colorectal Cancer. J Natl Cancer Inst. 2017; 109(8). PMC: 5963831. DOI: 10.1093/jnci/djw332. View

Richmond O, Ghotbaddini M, Allen C, Walker A, Zahir S, Powell J . The aryl hydrocarbon receptor is constitutively active in advanced prostate cancer cells. PLoS One. 2014; 9(4):e95058. PMC: 3995675. DOI: 10.1371/journal.pone.0095058. View

Shourideh M, DePriest A, Mohler J, Wilson E, Koochekpour S . Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line. Prostate. 2016; 76(12):1067-77. DOI: 10.1002/pros.23190. View

Hankey W, Frankel W, Groden J . Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting. Cancer Metastasis Rev. 2018; 37(1):159-172. PMC: 5803335. DOI: 10.1007/s10555-017-9725-6. View

Schneider J, Logan S . Revisiting the role of Wnt/β-catenin signaling in prostate cancer. Mol Cell Endocrinol. 2017; 462(Pt A):3-8. PMC: 5550366. DOI: 10.1016/j.mce.2017.02.008. View

Qiu W, Hu Y, Andersen T, Jafari A, Li N, Chen W . Tumor necrosis factor receptor superfamily member 19 (TNFRSF19) regulates differentiation fate of human mesenchymal (stromal) stem cells through canonical Wnt signaling and C/EBP. J Biol Chem. 2010; 285(19):14438-49. PMC: 2863178. DOI: 10.1074/jbc.M109.052001. View

Takayama K, Suzuki T, Tsutsumi S, Fujimura T, Urano T, Takahashi S . RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer. Oncotarget. 2014; 6(4):2263-76. PMC: 4385850. DOI: 10.18632/oncotarget.2949. View

10.

He M, Cuoco M, Crowdis J, Bosma-Moody A, Zhang Z, Bi K . Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med. 2021; 27(3):426-433. PMC: 7960507. DOI: 10.1038/s41591-021-01244-6. View

11.

Leibold J, Ruscetti M, Cao Z, Ho Y, Baslan T, Zou M . Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis. Cancer Discov. 2020; 10(7):1038-1057. PMC: 7334089. DOI: 10.1158/2159-8290.CD-19-1242. View

12.

Stanbrough M, Bubley G, Ross K, Golub T, Rubin M, Penning T . Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006; 66(5):2815-25. DOI: 10.1158/0008-5472.CAN-05-4000. View

13.

Stanford E, Wang Z, Novikov O, Mulas F, Landesman-Bollag E, Monti S . The role of the aryl hydrocarbon receptor in the development of cells with the molecular and functional characteristics of cancer stem-like cells. BMC Biol. 2016; 14:20. PMC: 4794823. DOI: 10.1186/s12915-016-0240-y. View

14.

Quigley D, Dang H, Zhao S, Lloyd P, Aggarwal R, Alumkal J . Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018; 174(3):758-769.e9. PMC: 6425931. DOI: 10.1016/j.cell.2018.06.039. View

15.

Schatoff E, Goswami S, Zafra M, Foronda M, Shusterman M, Leach B . Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition. Cancer Discov. 2019; 9(10):1358-1371. PMC: 6774804. DOI: 10.1158/2159-8290.CD-19-0289. View

16.

Dehm S, Hillman D, Sicotte H, Tan W, Gormley M, Bhargava V . A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann Oncol. 2017; 29(2):352-360. PMC: 6304474. DOI: 10.1093/annonc/mdx689. View

17.

Kumar A, Coleman I, Morrissey C, Zhang X, True L, Gulati R . Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 2016; 22(4):369-78. PMC: 5045679. DOI: 10.1038/nm.4053. View

18.

Zhang Z, Cheng L, Li J, Farah E, Atallah N, Pascuzzi P . Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer. Cancer Res. 2018; 78(12):3147-3162. PMC: 6004251. DOI: 10.1158/0008-5472.CAN-17-3006. View

19.

Bierie B, Nozawa M, Renou J, Shillingford J, Morgan F, Oka T . Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene. 2003; 22(25):3875-87. DOI: 10.1038/sj.onc.1206426. View

20.

Murillo-Garzon V, Kypta R . WNT signalling in prostate cancer. Nat Rev Urol. 2017; 14(11):683-696. DOI: 10.1038/nrurol.2017.144. View